# Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

> **NCT00748605** · PHASE2 · COMPLETED · sponsor: **Shionogi** · enrollment: 842 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** S-2367 Placebo
- **DRUG:** S-2367 1600 mg q.d. 54 Weeks
- **DRUG:** S-2367 1600 mg q.d. 60 weeks
- **OTHER:** LCD (low calorie diet)
- **OTHER:** RCD (reduced calorie diet)

## Key facts

- **NCT ID:** NCT00748605
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-11
- **Final completion:** 2009-01
- **Target enrollment:** 842 (ACTUAL)
- **Last updated:** 2018-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748605, "Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00748605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*